Citigroup Reiterates Buy Rating on Edwards Lifesciences Corporation (EW)

Market Context

Edwards Lifesciences Corporation operates in the Healthcare sector. The stock currently trades at $93.52 with a market capitalization of $49.5B. The stock has gained 14.5% over the past 52 weeks.

Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Edwards Lifesciences Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Edwards Lifesciences Corporation

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 08, 2026	Citigroup	Buy	N/A
Jul 06, 2026	Evercore ISI Group	Outperform	N/A
Jun 30, 2026	BTIG	Buy	N/A
Jun 16, 2026	RBC Capital	Outperform	N/A
Jun 02, 2026	TD Cowen	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View EW Stock Page